IL-4 mRNA expression in Laryngeal Squamous Cell Carcinoma patients with or without lymph node involvement
Orginal.jpg

Received: 11 Oct 2013

Revised: 19 Nov 2013

Accepted: 22 Dec 2013

 

IL-4 mRNA Expression in Laryngeal Squamous Cell Carcinoma Patients with or without Lymph Node Involvement

 

Esmael Amirazodi1, Mahboobeh Razmkhah1, Mansoureh Jaberipour1, Ahmad Hosseini1, Bijan Khademi2

 

1Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.

2Department of ENT, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.

Abstract

 

Background: Interleukin (IL)-4 is a member of T helper 2 (Th2) axis produced by T-lymphocytes and mast cells. It has been shown that IL-4 expression changes in tumor tissues. The main objective of this study is to investigate the expression of IL-4 mRNA in patients with Laryngeal Squamous Cell Carcinoma (LSCC) with or without lymph node involvement. Materials and Methods: mRNA expression of IL-4 in LSCC tissues were detected by quantative Real-Time PCR (qRT-PCR). Expression of IL-4 gene was compared between lymph node positive and negative patients with Squamous Cell Carcinoma of Larynx. Results: No statistically significant association was found in expression of IL-4 between lymph node positive and negative patients. Conclusion: It seems that IL-4 has no important effect on the involvement of lymph node in LSCC. However, to achieve a definite conclusion more investigations are certainly required. [GMJ. 2014;3(1):20-23]

 

Keywords: Cancer; Interleukin-4; Lymph Node Metastasis; Larynx; T helper 2

Introduction

 

Laryngeal cancer consists of some types of squamous cell carcinoma (SCC). Sarcoma and laryngeal lymphoma are other malignancies of larynx which are rare [1]. Laryngeal cancer is responsible for one fourth of all head and neck cancers, and is 4 times more common in males than in females [2]. Almost 10-15% of patients with laryngeal cancer have metastases to lung, liver and skeletal system when they are referred [3]. Thus, novel ways of detection and treatment are absolutely required and should be investigated [4].

Cytokines would change in different strategic sites such as peripheral blood, lymph nodes (LN) and tissues of patients with cancer. Interleukin (IL)-4 is one of T helper 2 (Th2) type cytokines with major roles in development of different types of cancer such as colon cancer, breast cancer, glioma, and melanoma [5]. IL-4 has a main role in differentiation of native T lymphocytes and causes the production of IL-4, IL-5, IL-10,and IL-13. These cytokines strongly inhibit the differentiation of interferon gamma (IFNγ) producing cells [6]. IL-4 inhibits IFNγ to stimulate macrophages; therefore, it inhibits cellular immunity [7].

Li et al. showed that endogenous IL-4 upregulates antiapoptotic genes and stimulates tumor growth, since using monoclonal antibody to neutralize IL-4 caused reduction of tumor growth [8]. Kanai et al. revealed that IL-4 decreases chorioembryonic antigen (CEA) and E-cadherin which may lead to lower attachment between colon tumor cells [9]. IL-4 has the ability to enhance lung metastases in rats with melanoma and injection of IL-4 has been shown to increase these metastases which would be ceased by using neutralizing IL-4 monoclonal antibodies [10]. Production of large amounts of IL-4 in tumor microenvironment compared to normal tissues can probably protect tumor cells against immune system [11]. In a study by Stassi and colleagues IL-4 was introduced as a reason for resistance of thyroid cancer cells to chemotherapy [12].

As IL-4 is one of the important cytokines known with cancer promoting characteristics such as metastasis to different organs, we aimed to investigate IL-4 gene in tumor tissues of laryngeal cancer patients with and without LN involvement. Results of this study would open new insights for LSCC tumor progression.

 

Materials and Methods

 

Sample Size and Sampling Method

This study was performed on tumor tissues from 58 patients with laryngeal cancer, among which 7 patients had LN involvement and 47 patients had no LN involvement. Patients underwent surgeries in Khalili hospital (Shiraz University of Medical Sciences, Shiraz, Iran) and 0.5 × 0.5 cm of tumour tissues were sent to the laboratory on ice. Those patients with a pathology diagnosis other than squamous cell carcinoma or with previous radiotherapy or chemotherapy were excluded from the study. After pathologist’s approval for squamous cell carcinoma, the samples were held at -70 oC till the lab studies were started.

RNA extraction and complementary DNA (cDNA) synthesis

A 500 mg frozen sample was powdered with liquid nitrogen and was then transferred to a 1.5 ml tube while RNA was extracted by using RNA extraction kit (Roche™, USA) based on the manufacturer’s instructions.

Finally optic density (OD) of extracted RNAs was determined using spectrophotometer. cDNA was produced from the extracted RNAs using the cDNA synthesis kit based on the manuscript (Fermentas™, Canada).

Quantitative Real Time Polymerase Chain Reaction (Q-PCR)

Q-PCR method was performed using an Applied Biosystem thermal cycler. Approximately 2 μl cDNA was amplified in each 25 μl PCR reaction containing 12.5 μl of 2x SYBR Green Master Mix (Fermentas™, Canada), 0.3 μl of each 10 pmol forward and reverse primers (designed in primer 3 software) and 9.9 μl DEPC water. PCR amplification was done in 50 cycles using the following program: 95ºC for 10 min, 95ºC for 15 s, 57 ºC for 30 s and 60 ºC for 34 s. Expression of 18S rRNA was used as reference gene.

 

Statistical Analysis

Statistical analyses were done using the SPSS software for windows version 15 (SPSS, Chicago, IL, USA). Non-parametric Mann-Whitney U test was used to compare the rate of gene expression of IL-4 between patients with and without LN involvement. The relative amounts of IL-4 transcripts were determined from ΔCt and 2−ΔCt formulas. Significant difference was accepted if P value was less than 0.05.

 

Results

 

Clinicopathological Characteristics of Patients

All 58 patients were male with a minimum age of 38 years old and maximum of 84 years old (mean age was 53± 12 years). 87% of the patients had LN involvement whereas 13% had no involvement.

 

IL-4 Transcripts and Lymph Node Involvement

As shown in Figure-1 the median of 2-ΔCT of IL-4 expression in tumor tissues of patients without LN involvement was slightly higher than those with LN involvement. However, this difference was not statistically significant (P value>0.05).

 

Discussion

 

Expression of cytokines in tumor tissues acts as one of the prominent factors mediating tumor growth and metastasis. Th2 type cytokines such as IL-4 favor tumor growth by stimulating cell proliferation and inhibiting cell apoptosis. Some studies showed a higher expression of Th2 cytokines in the serum of patients with cancer. Mojtahedi and colleagues studied serum level of IL-4 and IL-10 in head and neck squamous cell carcinoma (HNSCC) patients and in a group of normal individuals. They showed that serum IL-4 is significantly higher in patients than controls [13]. Similarly, Cheng et al. detected much higher expression of IL-4 in the serum of patients with nasopharyngeal cancer [14]. Peripheral blood mononuclear cells (PBMC) of laryngeal squamous cell carcinoma patients also showed higher level of IL-4 mRNA in comparison with control subjects [15]. Interestingly, Manchanda studied tobacco related SCC of oral cavity and revealed that T-lymphocytes of these patients had significantly higher expression of IL-4 than control group [16]. Recently, Seto et al. designed a peptide against IL-4 receptor and found out that this peptide has the ability to decrease the rate of tumor growth in mice with HNSCC [17]. In contrast, Myers and co-workers showed much more increase in tumor growth in 6 cell lines of HNSCC in response to IL-4 [18].

In this study we aimed to evaluate the expression of IL-4 mRNA in tumor tissues of patients with LSCC and its relationship with LN involvement in these patients. Based on the results of our study, no relationship was found between IL-4 gene expression in tumor tissues of LSCC patients and LN involvement. Consistently, Oliveira et al. reported no significant relation between clinicopathological characteristics of patients with invasive oral SCC and IL-4 expression [19]. Similarly, it has been determined that the immune system of patients with HNSCC has a shift toward Th2 type responses with increased level of IL-4, IL-6 and IL-10 but without relationship with important tumor prognostic factors [20].

 

Conclusion

 

In conclusion, it would be reasonable to say that IL-4 may have no effect on LN involvement in LSCC patients and it could not be used as a biomarker for prognosis in these patients. However, there were some limitations such as type of technique and sample size in our study which may have important effects on this result. Thus, using more accurate techniques such as western blot compared to real time PCR and study on a larger sample size contribute to the better elucidation.

 

Acknowledgment

 

This work was financially supported by a grant from Shiraz Institute for Cancer Research (ICR-100-504) and by Shiraz University of medical Sciences (Grant No. 90-3908).

 

Declaration of interest

 

The authors report no conflicts of interest.

 

Correspondence to:

Mahboobeh Razmkhah, Shiraz Institute for Cancer Research,School of Medicine, Shiraz University of Medical Sciences

Telephone Number: (+98) 711 230 3687

Email Address : razmkhahm@sums.ac.ir

GMJ. 2014;3(1):20-23

www.gmj.ir

C:\Users\Hossein\Downloads\159-898-3-ED.tif

Figure 1. Expression of IL-4 mRNA in tumor tissues of laryngeal squamous cell carcinoma patients with and without lymph node involvement. Horizontal lines showed the median of 2-ΔCT.

 

References

  1. 1. Jacobs C. The internist in the management of head and neck cancer. Ann Intern Med. 1990;113(10):771-8.
  2. 2. Jemel A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.
  3. 3. Amusa YB, Badmus A, Olabanji JK, Oyebamiji EO. Laryngeal carcinoma: experience in Ile-Ife, Nigeria. Niger J Clin Pract. 2011;14(1):74-8.
  4. 4. Hoffman HT, Porter K, Karnell LH, Cooper JS, Weber RS, Langer CJ, et al. Laryngeal cancer in the United States: changes in demographics, patterns of care, and survival. Laryngoscope. 2006;116(s111):1-13.
  5. 5. Podhajcer OL, Lopez MV, Mazzolini G. Cytokine gene transfer for cancer therapy. Cytokine Growth Factor Rev. 2007;18(1-2):183-94.
  6. 6. Nelms K, Keegan AD, Zamorano J, Ryan JJ, Paul WE. The IL-4 receptor: signalling mechanisms and biologic functions. Annu Rev Immunol. 1999;17:701-38.
  7. 7. Abbas AK, Lichtman AH, Pillai S. Cellular and molecular immunology. 7th ed. New York: Saunders; 2011. P.130-4.
  8. 8. Li Z, Jiang J, Wang Z, Zhang J, Xiao M, Wang C, et al. Endogenous interleukin-4 promotes tumor development by increasing tumor cell resistance to apoptosis. Cancer Res. 2008;68(21):8687-94.
  9. 9. T Kanai, M Watanabe, A Hayashi, A Nakazawa, T Yajima, A Okazawa, et al. Regulatory effect of interleukin-4 and interleukin-13 on colon cancer cell adhesion. Br J Cancer. 2000;82(10):1717-23.
  10. 10. Kobayashi M, Kobayashi H, Pollard RB, Suzuki F. A pathogenic role of Th2 cells and their cytokine products on the pulmonary metastasis of murine B16 melanoma. J Immunol. 1998;160(12):5869-73.
  11. 11. Razmkhah M, Jaberipour M, Erfani N, Habibagahi M, Talei AR, Ghaderi A. Adipose derived stem cells (ASCs) isolated from breast cancer tissue express IL-4, IL-10 and TGF-β1 and upregulate expression of regulatory molecules on T cells: do they protect breast cancer cells from the immune response? Cell Immunol. 2011;266(2):116-22.
  12. 12. Stassi G, Todaro M, Zerilli M, Ricci-Vitiani L, Di Liberto D, Patti M, et al. Thyroid cancer resistance to chemotherapeutic drugs via autocrine production of interleukin-4 and interleukin-10. Cancer Res. 2003;63(20):6784-90.
  13. 13. Mojtahedi Z, Khademi B, Yehya A, Talebi A, Fattahi MJ, Ghaderi A. Serum levels of interleukins 4 and 10 in head and neck squamous cell carcinoma. J Laryngol Otol. 2012;126(2):175-9.
  14. 14. Cheng G, Shao JY, Chen Z, Zeng RP, He YS. Study of immunological indicators in peripheral blood for nasopharyngeal carcinoma. Di Yi Jun Yi Da Xue Xue Bao. 2002;22(12):1104-5.
  15. 15. Deng G, Yang C, Chen W. Expression of Th1/th2 transcription factors and cytokines in laryngeal squamous cell carcinoma and its clinical significance. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2012;26(6):270-3.
  16. 16. Manchanda P, Sharma SC, Das SN. Differential regulation of IL-2 and IL-4 in patients with tobacco-related oral squamous cell carcinoma. Oral Dis. 2006;12(5):455-62.
  17. 17. Seto K, Shoda J, Horibe T, Warabi E, Ishige K, Yamagata K, et al. Interleukin-4 receptor α-based hybrid peptide effectively induces antitumor activity in head and neck squamous cell carcinoma. Oncol Rep. 2013;29(6):2147-53.
  18. 18. Myers JN, Yasumura S, Suminami Y, Hirabayashi H, Lin Wc, Johnson JT, et al. Growth stimulation of human head and neck squamous cell carcinoma cell lines by interleukin 4. Clin Cancer Res. 1996;2(1):127-35.
  19. 19. Oliveira MV, Fraga CA, Gomez RS, Paula AM. Immunohistochemical expression of interleukin-4, -6, -8, and -12 in inflammatory cells in surrounding invasive front of oral squamous cell carcinoma. Head Neck. 2009;31(11):1439-46.
  20. 20. Lathers DM, Achille NJ, Young MR. Incomplete Th2 skewing of cytokines in plasma of patients with squamous cell carcinoma of the head and neck. Hum Immunol. 2003;64(12):1160-6.
  21.  

Refbacks

  • There are currently no refbacks.